These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://minarutj390324.bluxeblog.com/71284259/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide